10x Genomics (TXG) Competitors $13.57 +0.23 (+1.72%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$13.72 +0.15 (+1.14%) As of 07:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TXG vs. ADPT, PACB, TWST, VCYT, BIO.B, VNT, MIR, ST, RAL, and CAMTShould you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Adaptive Biotechnologies (ADPT), Pacific Biosciences of California (PACB), Twist Bioscience (TWST), Veracyte (VCYT), Bio-Rad Laboratories (BIO.B), Vontier (VNT), Mirion Technologies (MIR), Sensata Technologies (ST), Ralliant (RAL), and Camtek (CAMT). 10x Genomics vs. Its Competitors Adaptive Biotechnologies Pacific Biosciences of California Twist Bioscience Veracyte Bio-Rad Laboratories Vontier Mirion Technologies Sensata Technologies Ralliant Camtek 10x Genomics (NASDAQ:TXG) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations. Does the media favor TXG or ADPT? In the previous week, 10x Genomics had 7 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 17 mentions for 10x Genomics and 10 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.36 beat 10x Genomics' score of 1.24 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 11 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TXG or ADPT more profitable? 10x Genomics has a net margin of -13.13% compared to Adaptive Biotechnologies' net margin of -59.07%. 10x Genomics' return on equity of -12.88% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -12.88% -10.03% Adaptive Biotechnologies -59.07%-60.93%-23.03% Do institutionals and insiders believe in TXG or ADPT? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, TXG or ADPT? 10x Genomics has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Do analysts rate TXG or ADPT? 10x Genomics currently has a consensus target price of $13.54, indicating a potential downside of 0.21%. Adaptive Biotechnologies has a consensus target price of $12.38, indicating a potential downside of 4.95%. Given 10x Genomics' higher possible upside, research analysts plainly believe 10x Genomics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Which has higher earnings & valuation, TXG or ADPT? Adaptive Biotechnologies has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.77-$182.63M-$0.70-19.39Adaptive Biotechnologies$178.96M11.08-$159.49M-$0.82-15.88 Summary10x Genomics beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks. Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXG vs. The Competition Export to ExcelMetric10x GenomicsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.66B$2.06B$5.76B$9.85BDividend YieldN/AN/A6.67%4.51%P/E Ratio-19.3938.2675.6126.43Price / Sales2.779.44550.93119.09Price / CashN/A52.1037.0558.92Price / Book2.3411.0511.246.06Net Income-$182.63M-$63.67M$3.29B$266.28M7 Day Performance-3.14%-2.48%0.20%-0.33%1 Month Performance1.95%5.27%6.31%3.43%1 Year Performance-41.36%34.04%56.09%23.10% 10x Genomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXG10x Genomics4.1523 of 5 stars$13.57+1.7%$13.54-0.2%-40.7%$1.66B$610.78M-19.391,240Positive NewsADPTAdaptive Biotechnologies3.3372 of 5 stars$12.67-2.5%$12.38-2.3%+199.3%$1.93B$205.22M-15.45790Positive NewsPACBPacific Biosciences of California1.9673 of 5 stars$1.32-4.3%$1.90+43.9%-6.1%$396.49M$154.01M-0.58730Positive NewsTWSTTwist Bioscience3.9095 of 5 stars$27.39-4.2%$49.40+80.4%-35.2%$1.65B$312.97M-18.89990Positive NewsVCYTVeracyte3.2045 of 5 stars$29.55-4.7%$40.90+38.4%+6.7%$2.32B$479.13M89.55790Positive NewsBIO.BBio-Rad LaboratoriesN/A$247.05flatN/A-24.4%$6.72B$2.57B21.068,200VNTVontier3.9305 of 5 stars$43.13-1.3%$47.50+10.1%+29.5%$6.33B$2.98B16.408,000MIRMirion Technologies1.5382 of 5 stars$20.69-0.6%$23.00+11.2%+104.0%$4.84B$860.80M689.672,860News CoveragePositive NewsSTSensata Technologies4.6278 of 5 stars$33.12-0.9%$34.64+4.6%-11.7%$4.82B$3.93B44.1619,000Positive NewsRALRalliantN/A$42.22-3.5%$55.17+30.7%N/A$4.76BN/A0.007,000News CoverageAnalyst ForecastCAMTCamtek3.3829 of 5 stars$82.58+0.1%$96.10+16.4%-6.4%$3.77B$471.59M30.25400 Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Pacific Biosciences of California Alternatives Twist Bioscience Alternatives Veracyte Alternatives Bio-Rad Laboratories Alternatives Vontier Alternatives Mirion Technologies Alternatives Sensata Technologies Alternatives Ralliant Alternatives Camtek Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXG) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
